DK382986A - Aktivering af makrofag tumoricid aktivitet med granulocytmakrofag kolonistimulationsfaktor - Google Patents

Aktivering af makrofag tumoricid aktivitet med granulocytmakrofag kolonistimulationsfaktor Download PDF

Info

Publication number
DK382986A
DK382986A DK382986A DK382986A DK382986A DK 382986 A DK382986 A DK 382986A DK 382986 A DK382986 A DK 382986A DK 382986 A DK382986 A DK 382986A DK 382986 A DK382986 A DK 382986A
Authority
DK
Denmark
Prior art keywords
granulocyte
stimulating factor
colony stimulating
macrophag
macrophage colony
Prior art date
Application number
DK382986A
Other languages
English (en)
Other versions
DK382986D0 (da
DK174603B1 (da
Inventor
Dirk M Anderson
Michael A Cantrell
Douglas P Cerretti
Iii Paul J Conlon
David J Cosman
Kenneth H Grabstein
Alf D Larsen
Virginia L Price
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27117812&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK382986(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DK382986D0 publication Critical patent/DK382986D0/da
Publication of DK382986A publication Critical patent/DK382986A/da
Application granted granted Critical
Publication of DK174603B1 publication Critical patent/DK174603B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK198603829A 1985-08-16 1986-08-11 Anvendelse af granulocyt makrofag kolonistimulerende faktor til fremstilling af et medikament til fremme af tumoricid aktivitet DK174603B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76689385A 1985-08-16 1985-08-16
US76689385 1985-08-16
US88899586 1986-07-31
US06/888,995 US5078996A (en) 1985-08-16 1986-07-31 Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor

Publications (3)

Publication Number Publication Date
DK382986D0 DK382986D0 (da) 1986-08-11
DK382986A true DK382986A (da) 1987-02-17
DK174603B1 DK174603B1 (da) 2003-07-14

Family

ID=27117812

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198603829A DK174603B1 (da) 1985-08-16 1986-08-11 Anvendelse af granulocyt makrofag kolonistimulerende faktor til fremstilling af et medikament til fremme af tumoricid aktivitet

Country Status (8)

Country Link
US (1) US5078996A (da)
EP (1) EP0211684B1 (da)
JP (1) JPH0780781B2 (da)
AT (1) ATE77958T1 (da)
AU (1) AU586876B2 (da)
CA (1) CA1341142C (da)
DE (1) DE3685918T2 (da)
DK (1) DK174603B1 (da)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2130493C1 (ru) * 1984-07-06 1999-05-20 Новартис Аг Способ получения белка с активностью gm-csf приматов
US5795568A (en) * 1984-09-19 1998-08-18 Novartis Corporation Method of treating infectious disease with GM-CSF
US5422105A (en) * 1985-02-05 1995-06-06 Cetus Oncology Corporation Use of recombinant colony stimulating factor 1
US5556620A (en) * 1985-02-05 1996-09-17 Cetus Oncology Corporation Use of recombinant colony stimulating factor-1 to enhance wound healing
US5837229A (en) * 1985-02-05 1998-11-17 Chiron Corporation Uses of recombinant colony stimulating factor-1
US5104650A (en) * 1985-02-05 1992-04-14 Cetus Corporation Uses of recombinant colony stimulating factor-1
US5093115A (en) * 1985-06-11 1992-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of preparing activated killer monocytes for treating colorectal cancer
US5391706A (en) * 1987-07-16 1995-02-21 Schering Plough Corporation Purification of GM-CSF
AU638204B2 (en) * 1987-11-12 1993-06-24 Schering Corporation Acceleration of bone formation with gm-csf
BE1002141A5 (fr) * 1988-01-13 1990-07-31 Bartholeyns Jacques Procede de culture et d'activation de cellules humaines et conditionnement pour le traitement du cancer.
JPH01193227A (ja) * 1988-01-29 1989-08-03 Res Dev Corp Of Japan 癌免疫療法補助剤
AU4219689A (en) * 1988-08-19 1990-03-23 Genetics Institute Inc. Treatment for malignant melanoma
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
ES2055314T3 (es) * 1989-01-30 1994-08-16 Schering Corp Tratamiento de disfuncion leucocitaria con gm-csf.
US5154921A (en) * 1990-07-13 1992-10-13 Dana-Farber Cancer Institute, Inc. Promotion of maturation of hematopoietic progenitor cells
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
US6001351A (en) * 1993-05-18 1999-12-14 I.D.M. Immuno-Designed Molecules Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
JP3454825B2 (ja) * 1993-05-18 2003-10-06 イ・デ・エム・イミュノ−デジネ・モレキュル 新規なマクロファージ、その製造方法、及び医薬組成物の活性物質としてのその用途
US6103694A (en) * 1995-07-21 2000-08-15 The United States Of America As Represented By The Department Of Health And Human Services Method of decreasing radiation of radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
US5800812A (en) * 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US6821516B1 (en) * 1997-07-18 2004-11-23 I.D.M. Immuno-Designed Molecules Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
JP2002529707A (ja) * 1998-11-03 2002-09-10 セル ジェネシス インコーポレイテッド 癌関連抗原およびそれらの同定の方法
ATE516046T1 (de) 1999-05-13 2011-07-15 Wyeth Corp Adjuvans kombinationsformulierungen
US8017590B1 (en) 1999-10-22 2011-09-13 Sanofi Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
SG143058A1 (en) * 2000-08-11 2008-06-27 Favrille Inc Method and composition for altering a t cell mediated pathology
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
SK5482003A3 (en) * 2000-11-10 2004-03-02 Wyeth Corp Adjuvant combination formulations
EP1421098A4 (en) * 2001-04-13 2006-03-15 Wyeth Corp SURFACE PROTEINS OF STREPTOCOCCUS PYOGENES
US20070128229A1 (en) * 2002-04-12 2007-06-07 Wyeth Surface proteins of Streptococcus pyogenes
EP2277897A1 (en) 2001-04-16 2011-01-26 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
IL163988A0 (en) * 2002-03-15 2005-12-18 Wyeth Corp Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
US20040141947A1 (en) 2002-10-16 2004-07-22 Hunter Samuel F. Method for treatment of demyelinating central nervous system disease
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US8071652B2 (en) * 2003-08-21 2011-12-06 The Board Of Regents Of The University Of Texas System Method of treating irritable bowel syndrome
EP1699810A4 (en) 2003-12-17 2009-10-21 Elan Pharm Inc BETWEEN BETA IMMUNOGENIC PEPTIDE CONJUGATES PRODUCTION TECHNIQUES OF THESE CONJUGATES
BRPI0417744B8 (pt) 2003-12-17 2021-05-25 Wyeth Corp método para produzir um conjugado imunogênico, e,conjugado imunogênico
US7968565B2 (en) * 2004-03-15 2011-06-28 Sunesis Pharmaceuticals, Inc. Therapeutic combinations comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
US20060036080A1 (en) * 2004-07-16 2006-02-16 Bossard Mary J Conjugates of GM-CSF moiety and a polymer
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
US20060057127A1 (en) * 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
EP2298341A3 (en) 2004-10-21 2011-07-13 Wyeth LLC Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
WO2006049599A1 (en) * 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy for atheromatous plaques using immune modulation
WO2006050058A2 (en) * 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy of inflamed tissues using immune modulation
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2007241023B2 (en) 2006-03-30 2013-11-28 University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
US20070231298A1 (en) * 2006-03-31 2007-10-04 Cell Genesys, Inc. Cytokine-expressing cancer immunotherapy combinations
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CN104027333B (zh) * 2006-06-12 2017-05-17 逊尼希思制药公司 治疗癌症的化合物和组合物
PL2495307T3 (pl) 2006-07-13 2018-07-31 Wyeth Llc Wytwarzanie czynnika krzepliwości krwi IX o polepszonym wzorze glikozylacji
JP5401319B2 (ja) * 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
WO2008140571A2 (en) * 2006-11-15 2008-11-20 Functional Genetics, Inc. Methods and compositions for treating influenza
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
JP5586235B2 (ja) 2007-03-02 2014-09-10 ワイス・エルエルシー ポリペプチドの産生のための細胞培養における銅およびグルタミン酸塩の使用
EP2117579A4 (en) * 2007-03-07 2011-08-24 Mayo Foundation TREATMENT OF CANCER USING A GRANULOCYTIC MACROPHAGE COLONY STIMULATING FACTOR
US20100255513A1 (en) * 2007-03-30 2010-10-07 Denson Lee A Serological markers of inflammatory bowel disease phenotype and disease progression
US20080267935A1 (en) * 2007-04-06 2008-10-30 Cell Genesys, Inc. AraC in combination with a cytokine-secreting cell and methods of use thereof
WO2009014708A2 (en) * 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US8425897B2 (en) * 2007-08-30 2013-04-23 Immutep S.A. Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
KR20110004354A (ko) * 2007-12-21 2011-01-13 와이어쓰 엘엘씨 유전자 변형된 약독화 수포성 구내염 바이러스, 이의 조성물 및 사용 방법
KR20110031343A (ko) 2008-06-20 2011-03-25 와이어쓰 엘엘씨 베타-용혈성 스트렙토코커스 균주로부터 유래된 ｏｒｆ1358을 사용하는 조성물 및 방법
AR074273A1 (es) * 2008-11-05 2011-01-05 Wyeth Corp Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo
KR101774062B1 (ko) 2009-06-22 2017-09-01 와이어쓰 엘엘씨 황색포도상구균 혈청형 5 및 8 협막 다당류 접합체 면역원성 조성물 및 이의 제조 방법
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
EP2335730A1 (en) 2009-12-18 2011-06-22 Deutsches Krebsforschungszentrum Fusion polypeptides and their use for prevention and treatment of cancer
HUE033071T2 (hu) 2010-06-04 2017-11-28 Wyeth Llc Vakcinakészítmények
DK3831406T3 (da) 2010-08-23 2024-06-17 Wyeth Llc Stabile formuleringer af Neisseria-Meningitidis-RLP2086-antigener
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
HUE047263T2 (hu) 2010-12-22 2020-04-28 Wyeth Llc Staphylococcus aureus antigének stabil immunogén készítményei
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR112014021658A2 (pt) 2012-03-09 2017-07-11 Pfizer composições de neisseria meningitidis e métodos das mesmas
US20150190499A1 (en) 2012-07-19 2015-07-09 Zoetis Llc Bovine influenza c virus compositions
AU2013295770A1 (en) 2012-07-27 2015-01-29 Zoetis Services Llc Tick toxin compositions
CA2943263C (en) 2012-12-20 2018-12-04 Pfizer Inc. Glycoconjugation process
US9724366B2 (en) 2012-12-30 2017-08-08 Carmel-Haifa University Economic Corporation Ltd CD11 B[low] macrophages and conditioned media thereof for treating cancer and/or fibrosis
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
WO2014151401A1 (en) 2013-03-15 2014-09-25 Zoetis Llc CROSS-PROTECTION OF BOVINES AGAINST B. trehalosi INFECTION BY A MULTI-VALENT VACCINE
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
CN106535930A (zh) 2014-03-11 2017-03-22 明尼苏达大学董事会 猪流行性腹泻病毒疫苗及其使用方法
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
BR112017017460A2 (pt) 2015-02-19 2018-04-10 Pfizer Inc. composições de neisseria meningitidis e métodos das mesmas
CN107466326B (zh) 2015-03-12 2021-10-15 硕腾服务有限责任公司 溶血素方法和组合物
IL297740A (en) 2015-05-04 2022-12-01 Pfizer Protein-polysaccharide conjugates of group b streptococcus, methods for preparing the conjugates, immunogenic preparations containing conjugates and their uses
EP3334454B1 (en) 2015-08-14 2022-10-19 Zoetis Services LLC Mycoplasma bovis compositions
WO2017123201A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
BR112019006900A2 (pt) 2016-10-05 2019-07-02 Zoetis Services Llc métodos de liofilização que proporcionam protozoários desidratados estáveis para o uso como potentes vacinas vivas
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
WO2018142280A2 (en) 2017-01-31 2018-08-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
US20230146256A1 (en) 2020-04-17 2023-05-11 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
WO2022043855A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
EP4241791A1 (en) 2022-03-07 2023-09-13 InnaTher Gene Therapy S.à.r.l. Combined gene and radio therapy for the treatment of cancer
EP4241790A1 (en) 2022-03-07 2023-09-13 InnaTher Gene Therapy S.à.r.l. Expression system for the treatment of cancer
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342828A (en) * 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
JPS59137417A (ja) * 1983-01-28 1984-08-07 Morinaga Milk Ind Co Ltd 人尿由来コロニ−形成刺激因子及びカリクレインの製造法
JPS59169489A (ja) * 1983-03-15 1984-09-25 Otsuka Pharmaceut Co Ltd ヒト培養株化細胞
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
DE3586826T2 (de) * 1984-11-20 1993-03-25 Schering Biotech Corp Cdna-klone, kodierend fuer peptide mit der wirksamkeit eines menschlichen granulocyte-, makrophage- und eosinophilzellenwachstumsfaktors.
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung

Also Published As

Publication number Publication date
US5078996A (en) 1992-01-07
ATE77958T1 (de) 1992-07-15
DE3685918D1 (de) 1992-08-13
JPS6289621A (ja) 1987-04-24
DE3685918T2 (de) 1993-02-04
EP0211684A3 (en) 1988-06-08
DK382986D0 (da) 1986-08-11
EP0211684B1 (en) 1992-07-08
EP0211684A2 (en) 1987-02-25
AU6103186A (en) 1987-02-19
DK174603B1 (da) 2003-07-14
JPH0780781B2 (ja) 1995-08-30
CA1341142C (en) 2000-11-21
AU586876B2 (en) 1989-07-27

Similar Documents

Publication Publication Date Title
DK382986A (da) Aktivering af makrofag tumoricid aktivitet med granulocytmakrofag kolonistimulationsfaktor
Hiltz et al. α-MSH peptides inhibit acute inflammation induced in mice by rIL-1β, rIL-6, rTNF-α and endogenous pyrogen but not that caused by LTB4, PAF and rIL-8
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
EP0317568A4 (en) Use of stimulation of granulocyte-macrophage colonies for obtaining a medicament for the treatment of bacterial diseases.
ATE74510T1 (de) Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
HUT38125A (en) Process for preparing lymphokines /cytotoxic factors/ and pharmaceutical compositions containing such active substance
NO880929D0 (no) Produksjon og bruk av il-6.
Hideo et al. Production of an interleukin-8-like chemokine by cytokine-stimulated rat NRK-49F fibroblasts and its suppression by anti-inflammatory steroids
Ralph et al. Molecular and biological properties of human macrophage growth factor, CSF-1
Rathjen et al. Differential effects of small tumour necrosis factor-alpha peptides on tumour cell cytotoxicity, neutrophil activation and endothelial cell procoagulant activity.
MY106603A (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
Grimm et al. The lymphokine-activated killer cell phenomenon: in vitro and in vivo studies
EP0502599A1 (en) Use of IL-4 to enhance the reparitive phase of wound healing and repair and to enhance the healing of infected wounds and the wounds of diabetic mammals
MY107071A (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
Hornicek et al. Production and partial characterization of interleukin 2 induced by periodic acid oxidation of lymphocyte membranes
Seki et al. Induction of eosinophil chemotactic factor production from human peripheral blood mononuclear cells by solubilized BALL-1, a B cell lymphoma line
IT1212658B (it) Procedimento per la purificazione di una sostanza fisiologicamente attiva avente attivita antitumorale
Uenoa et al. AB Cell Lymphoma Line, BALL-1 Stimulates! Cells to Produce a Unique Eosinophil Chemotactic Factor
Iwasaka et al. Antitumor activities of human recombinant Interferon‐γ against cervical tumor transplanted into nude mice
DK0409040T3 (da) Kolonistimulerende faktoraktivitetspromotorer
Fujikawa et al. Augmentation of depressed lymphokine activated killer activity by continuous intravenous-administration of recombinant interleukin 2 to patients with hepatocellular carcinoma
DE68918197D1 (de) Methode zur Herstellung von rekombinantem menschlichem beta-Interleukin-1 in homogener Form.
Arimoto et al. Effect of Combination Therapy with OK-432 and Recombinant Interleukin-2 (rIL-2) by Splenic Injection to Inhibit Liver Metastasis on Mouse Model In Comparison to Subcutaneous Injection
IT1283945B1 (it) Uso dell'interferone alfa naturale umano da cellule linfoblastoidi per la terapia delle epatiti virali, neoplasie e sindromi da

Legal Events

Date Code Title Description
PUP Patent expired